Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
rrr1 Member Profile
 
Followed By 68
Posts 4,953
Boards Moderated 3
Alias Born 12/27/10
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 2:16:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/21/2020 9:33:35 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2020 9:03:05 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/28/2020 9:30:58 AM
Cannabis and CBD Stocks are Old News, The Next Hot Peripheral Sector is Here! InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2020 2:21:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/1/2020 4:39:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2020 12:00:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/6/2020 12:01:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/27/2020 12:01:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/13/2020 4:06:02 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/13/2020 4:02:49 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 12/26/2019 5:19:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/26/2019 5:16:58 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 12/16/2019 8:32:20 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 9:24:21 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/22/2019 6:01:03 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 10/17/2019 5:24:36 PM
Annual Report (10-k) Edgar (US Regulatory) - 9/30/2019 4:38:42 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/20/2019 4:36:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2019 4:34:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:52:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/6/2019 4:51:57 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/13/2019 4:11:11 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 8/2/2019 4:29:30 PM
rrr1   Tuesday, 05/19/20 07:35:02 AM
Re: None
Post # of 299748 
Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility; Demonstrates Potent and Rapid Virucidal Activity


Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19
WAKEFIELD, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that its anti-SARS-CoV-2 (COVID-19) drug candidate, Brilacidin, in an in vitro experiment using VERO cells, reduced the viral titer (load) of SARS-CoV-2 by 75 percent after only 1 hour of preincubation prior to infection at a concentration of 10µM as compared to vehicle control.
These statistically significant lab results strongly support Brilacidin’s prophylactic treatment potential given the drug’s potent and rapid virucidal activity—a unique ability, different from any other known drug currently in development to treat COVID-19, to inactivate the novel coronavirus prior to host cell entry and subsequent viral replication. A majority of antiviral agents targeting SARS-CoV-2 attempt to inhibit viral replication rather than completely eliminating the virus (virustatic versus virucidal).
Additional time-dependent and concentration-dependent experiments are underway to further delineate Brilacidin’s virucidal properties against SARS-CoV-2.
The review article linked below more broadly supports the therapeutic and prophylactic potential of Host Defense Proteins/Antimicrobial Peptides and their mimetics, like Brilacidin, against coronaviruses.
Memariani H, Memariani M. “Therapeutic and Prophylactic Potential of Anti-Microbial Peptides Against Coronaviruses.” Ir J Med Sci. 2020 Apr 18: 1–2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165072/
Brilacidin anti-SARS-CoV-2 research is part of ongoing antiviral studies that are being conducted at a U.S. Regional Biocontainment Laboratory (RBL). An earlier 16-hour post-infection experiment, in VERO cells, showed Brilacidin exhibited a dose-dependent reduction in SARS-CoV-2 infectious viral titers.
The Company is encouraged by Brilacidin’s considerable antiviral potential and believes that its use as a possible potent prophylactic and therapeutic antiviral agent for SARS-CoV-2, and other viruses, is warranted.
Separately, the Company and laboratory researchers (from a different testing facility) agreed that Brilacidin as a vaccine would not be studied further at this time. While the vaccine pathway remains of interest, the Company is prioritizing Brilacidin’s clinical development as a potential novel COVID-19 treatment, and thus is taking steps to rapidly advance Brilacidin into human trials.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist